Cargando…

The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis

BACKGROUND: There has always been a controversy on the hepatectomy for huge hepatocellular carcinoma (HCC). Therefore, we aim to explore the hepatectomy efficacy of huge HCC and its risk factors. METHODS: A systematic research was performed using PubMed, MedLine, Web of Knowledge, and Cochrane Libra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Liu, Zhiqiang, Liu, Xiaolong, Zeng, Yongyi, Liu, Jingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392948/
https://www.ncbi.nlm.nih.gov/pubmed/29384907
http://dx.doi.org/10.1097/MD.0000000000009226
_version_ 1783398590089003008
author Wang, Lei
Liu, Zhiqiang
Liu, Xiaolong
Zeng, Yongyi
Liu, Jingfeng
author_facet Wang, Lei
Liu, Zhiqiang
Liu, Xiaolong
Zeng, Yongyi
Liu, Jingfeng
author_sort Wang, Lei
collection PubMed
description BACKGROUND: There has always been a controversy on the hepatectomy for huge hepatocellular carcinoma (HCC). Therefore, we aim to explore the hepatectomy efficacy of huge HCC and its risk factors. METHODS: A systematic research was performed using PubMed, MedLine, Web of Knowledge, and Cochrane Library from their establishment to August 2017. The major endpoints were overall survival (OS) rate and recurrence-free survival (RFS) rate, and the secondary ones were the morbidity of complications and mortality of hepatectomy. RESULTS: About 13 studies with a total of 7609 patients were included in this meta-analysis. The hepatectomy efficacy of huge HCC was inferior to non-huge HCC both in OS (hazard ratio [HR] = 2.18, 95% confidence interval [CI] = 1.90–2.50, P < .00001; I(2) = 66%, P = .003) and RFS (HR = 1.97, 95% CI = 1.76–2.19, P < .00001; I(2) = 74%, P = .0001). However, the risk difference[RD] of the 1-year, 3-year and 5-year OS tended to be acceptable (RD = −0.05, 95% CI = −0.11–0.00, P = .05; RD = −0.13, 95% CI = −0.21–−0.05, P = .002; RD = −0.10, 95% CI = −0.19–−0.01, P = .03; respectively). Moreover, there were also no significant differences between huge HCC and non-huge HCC in the morbidity of complication and mortality of hepatectomy (RD = 0.07, 95% CI = −0.09–0.23, P = .38; RD = −0.01, 95% CI = −0.00–−0.03, P = .06; respectively). Related risk factors were measured to explore the differences, and the results showed that the level of alpha fetal protein (AFP) and the margin-positive rate were higher (standard mean difference [SMD] = 0.57, 95% CI = 0.26–0.88, P = .0003; odd radio[OR] = 32.52, 95% CI = 1.02–6.22, P = .04; respectively), the characteristic of huge HCC tended to be worse such as lower clinical or pathological stage, incomplete capsule and incorporate satellite metastases (OR = 2.91, 95% CI = 1.68–5.04, P = .001; OR = 3.99, 95% CI = 3.40–4.67, P < .00001; OR = 2.52, 95% CI = 1.66–3.83, P < .0001; respectively), and the rate of micorvascular invasion (MVI) including portal vein tumor thrombus (PVTT) were higher (OR = 3.36, 95% CI = 1.61–7.02, P = .001; OR = 2.75, 95% CI = 2.29–3.31, P < .00001; respectively) in the huge HCC. CONCLUSION: The hepatectomy efficacy of huge HCC was inferior to non-huge HCC, but its survival benefits and feasibility were confirmed in this meta-analysis. In addition, higher level of AFP, positive margin, lower clinical or pathological stage, incomplete capsule, incorporate satellite metastasis and MVI were significantly correlated with poor OS.
format Online
Article
Text
id pubmed-6392948
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63929482019-03-15 The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis Wang, Lei Liu, Zhiqiang Liu, Xiaolong Zeng, Yongyi Liu, Jingfeng Medicine (Baltimore) Research Article BACKGROUND: There has always been a controversy on the hepatectomy for huge hepatocellular carcinoma (HCC). Therefore, we aim to explore the hepatectomy efficacy of huge HCC and its risk factors. METHODS: A systematic research was performed using PubMed, MedLine, Web of Knowledge, and Cochrane Library from their establishment to August 2017. The major endpoints were overall survival (OS) rate and recurrence-free survival (RFS) rate, and the secondary ones were the morbidity of complications and mortality of hepatectomy. RESULTS: About 13 studies with a total of 7609 patients were included in this meta-analysis. The hepatectomy efficacy of huge HCC was inferior to non-huge HCC both in OS (hazard ratio [HR] = 2.18, 95% confidence interval [CI] = 1.90–2.50, P < .00001; I(2) = 66%, P = .003) and RFS (HR = 1.97, 95% CI = 1.76–2.19, P < .00001; I(2) = 74%, P = .0001). However, the risk difference[RD] of the 1-year, 3-year and 5-year OS tended to be acceptable (RD = −0.05, 95% CI = −0.11–0.00, P = .05; RD = −0.13, 95% CI = −0.21–−0.05, P = .002; RD = −0.10, 95% CI = −0.19–−0.01, P = .03; respectively). Moreover, there were also no significant differences between huge HCC and non-huge HCC in the morbidity of complication and mortality of hepatectomy (RD = 0.07, 95% CI = −0.09–0.23, P = .38; RD = −0.01, 95% CI = −0.00–−0.03, P = .06; respectively). Related risk factors were measured to explore the differences, and the results showed that the level of alpha fetal protein (AFP) and the margin-positive rate were higher (standard mean difference [SMD] = 0.57, 95% CI = 0.26–0.88, P = .0003; odd radio[OR] = 32.52, 95% CI = 1.02–6.22, P = .04; respectively), the characteristic of huge HCC tended to be worse such as lower clinical or pathological stage, incomplete capsule and incorporate satellite metastases (OR = 2.91, 95% CI = 1.68–5.04, P = .001; OR = 3.99, 95% CI = 3.40–4.67, P < .00001; OR = 2.52, 95% CI = 1.66–3.83, P < .0001; respectively), and the rate of micorvascular invasion (MVI) including portal vein tumor thrombus (PVTT) were higher (OR = 3.36, 95% CI = 1.61–7.02, P = .001; OR = 2.75, 95% CI = 2.29–3.31, P < .00001; respectively) in the huge HCC. CONCLUSION: The hepatectomy efficacy of huge HCC was inferior to non-huge HCC, but its survival benefits and feasibility were confirmed in this meta-analysis. In addition, higher level of AFP, positive margin, lower clinical or pathological stage, incomplete capsule, incorporate satellite metastasis and MVI were significantly correlated with poor OS. Wolters Kluwer Health 2017-12-29 /pmc/articles/PMC6392948/ /pubmed/29384907 http://dx.doi.org/10.1097/MD.0000000000009226 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Wang, Lei
Liu, Zhiqiang
Liu, Xiaolong
Zeng, Yongyi
Liu, Jingfeng
The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title_full The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title_fullStr The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title_full_unstemmed The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title_short The hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: A meta analysis
title_sort hepatectomy efficacy of huge hepatocellular carcinoma and its risk factors: a meta analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392948/
https://www.ncbi.nlm.nih.gov/pubmed/29384907
http://dx.doi.org/10.1097/MD.0000000000009226
work_keys_str_mv AT wanglei thehepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liuzhiqiang thehepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liuxiaolong thehepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT zengyongyi thehepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liujingfeng thehepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT wanglei hepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liuzhiqiang hepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liuxiaolong hepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT zengyongyi hepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis
AT liujingfeng hepatectomyefficacyofhugehepatocellularcarcinomaanditsriskfactorsametaanalysis